Perceptive Advisors - Q3 2023 holdings

$3 Billion is the total value of Perceptive Advisors's 97 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 33.7% .

 Value Shares↓ Weighting
FOLD BuyAMICUS THERAPEUTICS INC$336,745,870
-3.1%
27,692,917
+0.1%
11.23%
+11.7%
CERE  CEREVEL THERAPEUTICS HLDNG I$220,229,445
-31.3%
10,088,3850.0%7.35%
-20.9%
IMVT BuyIMMUNOVANT INC$146,445,987
+205.9%
3,814,691
+51.1%
4.88%
+252.5%
SellARCELLX INC$142,299,291
+12.0%
3,965,978
-1.3%
4.75%
+29.1%
BuyNUVALENT INC$113,244,842
+22.4%
2,463,451
+12.2%
3.78%
+41.0%
BuySOLENO THERAPEUTICS INC$90,729,734
+857.9%
3,074,542
+39.3%
3.03%
+1004.4%
 LIANBIOsponsored ads$85,762,091
-34.6%
57,558,4510.0%2.86%
-24.7%
AKRO SellAKERO THERAPEUTICS INC$81,910,517
-9.6%
1,619,425
-16.6%
2.73%
+4.2%
INBX BuyINHIBRX INC$78,099,508
-17.0%
4,256,104
+17.4%
2.60%
-4.3%
ALDX  ALDEYRA THERAPEUTICS INC$75,818,568
-20.4%
11,350,0850.0%2.53%
-8.2%
ARGX BuyARGENX SEsponsored adr$74,039,478
+175.3%
150,600
+118.3%
2.47%
+217.5%
PCVX SellVAXCYTE INC$68,453,446
-15.1%
1,342,751
-16.8%
2.28%
-2.1%
VRNA SellVERONA PHARMA PLCsponsored ads$65,317,311
-29.7%
4,007,197
-8.9%
2.18%
-19.0%
CBAY BuyCYMABAY THERAPEUTICS INC$60,283,978
+47.5%
4,043,191
+8.3%
2.01%
+70.0%
MGTX  MEIRAGTX HLDGS PLC$55,635,715
-26.9%
11,331,1030.0%1.86%
-15.8%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$54,431,367
-44.9%
11,962,938
-14.8%
1.82%
-36.5%
LYRA  LYRA THERAPEUTICS INC$49,882,067
-4.9%
12,757,5620.0%1.66%
+9.6%
SellAMYLYX PHARMACEUTICALS INC$49,233,265
-53.2%
2,688,873
-44.8%
1.64%
-46.0%
BBIO  BRIDGEBIO PHARMA$46,119,363
+53.3%
1,748,9330.0%1.54%
+76.6%
MDT BuyMEDTRONIC PLC$45,997,320
+11.8%
587,000
+25.7%
1.53%
+28.8%
BuyROIVANT SCIENCES LTD$44,611,246
+41.3%
3,819,456
+22.0%
1.49%
+62.8%
BuyDISC MEDICINE INC$42,077,214
+27.6%
895,641
+20.6%
1.40%
+47.0%
IMTX  IMMATICS N.V$40,431,570
+0.3%
3,491,5000.0%1.35%
+15.7%
NewAPOGEE THERAPEUTICS INC$38,934,2911,827,901
+100.0%
1.30%
CRNX SellCRINETICS PHARMACEUTICALS IN$37,583,389
+7.1%
1,263,732
-35.1%
1.25%
+23.5%
RVMD NewREVOLUTION MEDICINES INC$36,587,2861,321,795
+100.0%
1.22%
SWTX SellSPRINGWORKS THERAPEUTICS INC$35,152,017
-12.8%
1,520,416
-1.1%
1.17%
+0.5%
AXSM BuyAXSOME THERAPEUTICS INC$33,662,449
+72.5%
481,649
+77.4%
1.12%
+98.8%
HRMY BuyHARMONY BIOSCIENCES HLDGS IN$32,648,948
+4.1%
996,306
+11.8%
1.09%
+19.9%
RAPT SellRAPT THERAPEUTICS INC$31,921,336
-25.4%
1,920,658
-16.1%
1.06%
-14.0%
RCKT BuyROCKET PHARMACEUTICALS INC$31,092,899
+33.9%
1,517,467
+29.9%
1.04%
+54.3%
NAUT  NAUTILUS BIOTECHNOLOGY INC$28,791,237
-18.3%
9,111,1510.0%0.96%
-6.0%
 ACRIVON THERAPEUTICS INC$28,755,122
-26.2%
3,007,8580.0%0.96%
-15.0%
NewTANGO THERAPEUTICS INC$27,237,5802,418,968
+100.0%
0.91%
ADMA SellADMA BIOLOGICS INC$25,003,862
-43.1%
6,984,319
-41.3%
0.83%
-34.4%
TMCI SellTREACE MED CONCEPTS INC$24,044,527
-57.6%
1,834,060
-17.3%
0.80%
-51.2%
TARS  TARSUS PHARMACEUTICALS INC$23,037,312
-1.7%
1,296,4160.0%0.77%
+13.3%
COGT SellCOGENT BIOSCIENCES INC$22,517,333
-28.5%
2,309,470
-13.2%
0.75%
-17.6%
SRPT BuySAREPTA THERAPEUTICS INC$22,149,318
+138.6%
182,720
+125.4%
0.74%
+174.7%
MIRM BuyMIRUM PHARMACEUTICALS INC$21,236,527
+36.5%
672,042
+11.7%
0.71%
+57.3%
BuyORCHESTRA BIOMED HLDGS INC$21,207,816
+47.6%
2,432,089
+18.5%
0.71%
+70.0%
XENE SellXENON PHARMACEUTICALS INC$21,093,800
-55.2%
617,500
-49.5%
0.70%
-48.3%
VRCA  VERRICA PHARMACEUTICALS INC$19,576,448
-32.7%
5,038,9830.0%0.65%
-22.4%
BuyBIOHAVEN LTD$19,554,838
+154.8%
751,820
+134.3%
0.65%
+193.7%
MDGL SellMADRIGAL PHARMACEUTICALS INC$18,201,987
-74.0%
124,637
-58.9%
0.61%
-70.0%
NBIX BuyNEUROCRINE BIOSCIENCES INC$17,914,725
+89.9%
159,242
+59.2%
0.60%
+119.0%
PTGX SellPROTAGONIST THERAPEUTICS INC$17,585,274
-56.7%
1,054,273
-28.3%
0.59%
-50.0%
CABA SellCABALETTA BIO INC$17,236,513
-13.6%
1,132,491
-26.7%
0.58%
-0.3%
NewRAYZEBIO INC$17,245,071776,805
+100.0%
0.58%
 ASTRIA THERAPEUTICS INC$16,333,387
-10.4%
2,189,4620.0%0.54%
+3.2%
RLAY  RELAY THERAPEUTICS INC$16,341,445
-33.0%
1,943,0970.0%0.54%
-22.8%
VRDN SellVIRIDIAN THERAPEUTICS INC$15,511,885
-63.3%
1,011,205
-43.1%
0.52%
-57.7%
CRY  ARTIVION INC$14,119,296
-11.8%
931,3520.0%0.47%
+1.7%
ESTA SellESTABLISHMENT LABS HLDGS INC$13,625,905
-53.3%
277,683
-34.7%
0.46%
-46.1%
EOLS NewEVOLUS INC$13,580,2211,485,801
+100.0%
0.45%
TCMD BuyTACTILE SYS TECHNOLOGY INC$9,935,584
-33.8%
707,159
+17.4%
0.33%
-23.9%
BMEA  BIOMEA FUSION$9,858,228
-37.3%
716,4410.0%0.33%
-27.7%
ATHA  ATHIRA PHARMA INC$9,690,501
-31.5%
4,797,2780.0%0.32%
-21.2%
NTRA SellNATERA INC$9,654,377
-51.0%
218,178
-46.2%
0.32%
-43.6%
SellZYMEWORKS INC$9,168,420
-56.1%
1,446,123
-40.1%
0.31%
-49.3%
 SOLID BIOSCIENCES INC$8,809,751
-51.9%
3,495,9330.0%0.29%
-44.5%
RYTM NewRHYTHM PHARMACEUTICALS INC$8,730,482380,828
+100.0%
0.29%
CMAX BuyCAREMAX INC$8,105,940
-31.7%
3,823,557
+0.2%
0.27%
-21.5%
PRTA SellPROTHENA CORP PLC$7,990,924
-36.6%
165,615
-10.3%
0.27%
-26.8%
OM SellOUTSET MED INC$7,202,310
-63.5%
661,977
-26.6%
0.24%
-58.0%
FUSN  FUSION PHARMACEUTICALS INC$7,153,627
-44.3%
2,751,3950.0%0.24%
-35.8%
 LANDOS BIOPHARMA INC$5,769,525
-7.8%
1,486,9910.0%0.19%
+6.1%
AKRO NewAKERO THERAPEUTICS INCcall$5,460,000800,000
+100.0%
0.18%
TERN NewTERNS PHARMACEUTICALS INC$5,407,2501,075,000
+100.0%
0.18%
 TYRA BIOSCIENCES INC$4,957,200
-19.1%
360,0000.0%0.16%
-6.8%
NBTX SellNANOBIOTIXsponsored ads$4,856,828
-9.6%
555,066
-47.6%
0.16%
+3.8%
AXGN SellAXOGEN INC$4,379,490
-67.3%
875,898
-40.2%
0.15%
-62.3%
 ENVVENO MEDICAL CORPORATION$4,212,905
+75.0%
781,6150.0%0.14%
+101.4%
XFOR  X4 PHARMACEUTICALS INC$3,864,545
-43.8%
3,545,4540.0%0.13%
-35.2%
NVAX NewNOVAVAX INCput$3,772,5201,300,000
+100.0%
0.13%
 SOMALOGIC INC$3,585,000
+3.5%
1,500,0000.0%0.12%
+20.0%
TVTX BuyTRAVERE THERAPEUTICS INC$3,576,000
+156.5%
400,000
+340.8%
0.12%
+197.5%
SRPT NewSAREPTA THERAPEUTICS INCcall$3,130,000100,000
+100.0%
0.10%
PNT BuyPOINT BIOPHARMA GLOBAL INCput$2,630,000
+289.6%
800,000
+60.0%
0.09%
+340.0%
ARQT  ARCUTIS BIOTHERAPEUTICS INCput$2,622,500
+85.0%
300,0000.0%0.09%
+112.2%
EYPT NewEYEPOINT PHARMACEUTICALS INCput$2,512,500750,000
+100.0%
0.08%
KRON  KRONOS BIO INC$2,278,568
-24.4%
1,752,7450.0%0.08%
-12.6%
FBRX NewFORTE BIOSCIENCES INC$2,161,6673,265,359
+100.0%
0.07%
 ACELYRIN INC$2,034,000
-51.3%
200,0000.0%0.07%
-43.8%
ETNB New89BIO INCcall$1,620,000400,000
+100.0%
0.05%
ACRS NewACLARIS THERAPEUTICS INCput$1,450,000500,000
+100.0%
0.05%
NewAEGLEA BIOTHERAPEUTICS INC$993,67181,116
+100.0%
0.03%
 VBI VACCINES INC CDA$925,507
-79.6%
1,381,3550.0%0.03%
-76.5%
OMIC  SINGULAR GENOMICS SYSTEMS IN$900,385
-54.1%
2,363,2140.0%0.03%
-47.4%
VERU BuyVERU INC$783,622
+632.7%
1,089,878
+1112.6%
0.03%
+766.7%
VKTX NewVIKING THERAPEUTICS INCcall$240,000300,000
+100.0%
0.01%
SellLEAP THERAPEUTICS INC$62,059
-96.6%
44,971
-92.3%
0.00%
-96.2%
APLS NewAPELLIS PHARMACEUTICALS INCput$72,500100,000
+100.0%
0.00%
 MOTUS GI HLDGS INC$40,512
-32.8%
90,0270.0%0.00%
-50.0%
BTAI ExitBIOXCEL THERAPEUTICS INCcall$0-439,500
-100.0%
0.00%
 EQRX INC*w exp 12/17/202$10,000
-76.5%
250,0000.0%0.00%
-100.0%
 SURROZEN INC*w exp 08/01/203$6,667
-33.3%
166,6660.0%0.00%
CMAXW  CAREMAX INC*w exp 06/08/202$11,250
-51.9%
60,0000.0%0.00%
-100.0%
XBI ExitSPDR SER TRput$0-150,000
-100.0%
-0.00%
VRNA ExitVERONA PHARMA PLCcall$0-500,000
-100.0%
-0.02%
MRTX ExitMIRATI THERAPEUTICS INCcall$0-200,000
-100.0%
-0.02%
QTRX ExitQUANTERIX CORP$0-130,000
-100.0%
-0.08%
ISEE ExitIVERIC BIO INC$0-168,000
-100.0%
-0.19%
VKTX ExitVIKING THERAPEUTICS INC$0-441,147
-100.0%
-0.21%
TERN ExitTERNS PHARMACEUTICALS INCput$0-1,075,000
-100.0%
-0.27%
ITCI ExitINTRA-CELLULAR THERAPIES INC$0-245,800
-100.0%
-0.45%
BMRN ExitBIOMARIN PHARMACEUTICAL INC$0-263,207
-100.0%
-0.66%
MRTX ExitMIRATI THERAPEUTICS INC$0-719,103
-100.0%
-0.75%
ILMN ExitILLUMINA INC$0-145,000
-100.0%
-0.79%
VIR ExitVIR BIOTECHNOLOGY INC$0-1,958,264
-100.0%
-1.39%
RETA ExitREATA PHARMACEUTICALS INCcl a$0-670,206
-100.0%
-1.98%
APLS ExitAPELLIS PHARMACEUTICALS INC$0-812,037
-100.0%
-2.14%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-10
42024-04-08
42024-04-03
SC 13D/A2024-04-03
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01

View Perceptive Advisors's complete filings history.

Compare quarters

Export Perceptive Advisors's holdings